CYXO.ST
Cyxone AB (publ) [CYXO.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CYXO.ST Stock Summary
Top 10 Correlated ETFs
CYXO.ST
Top 10 Correlated Stocks
CYXO.ST
In the News
CYXO.ST Financial details
Company Rating
Sell
Market Cap
9.35M
Income
-24.06M
Revenue
0
Book val./share
0.3
Cash/share
0.14
Dividend
-
Dividend %
-
Employees
7
Optionable
No
Shortable
Yes
Earnings
12 May 2023
P/E
-0.3
Forward P/E
-
PEG
0.06
P/S
-
P/B
0.23
P/C
0.62
P/FCF
-0.21
Quick Ratio
4.04
Current Ratio
4.27
Debt / Equity
0.02
LT Debt / Equity
-
-
-
EPS (TTM)
-0.23
EPS next Y
-
EPS next Q
-
EPS this Y
-48.84%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-21.75%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
2.65%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-68%
ROE
-65%
ROC
-0.77%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.078-0.78
52W High
-
52W Low
-
RSI
49
Rel Volume
0.26
Avg Volume
1.43M
Volume
372.59K
Perf Week
-1.36%
Perf Month
-6.67%
Perf Quarter
-51.45%
Perf Half Y
-48.94%
-
-
-
-
Beta
0.625145
-
-
Volatility
0%, 0%
Prev Close
-2.91%
Price
0.0868
Change
-4.19%
CYXO.ST Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0.07 | 0 | |
| Net income per share | -0.75 | -0.79 | -0.71 | -0.43 | -0.22 | |
| Operating cash flow per share | -0.75 | -0.73 | -0.68 | -0.42 | -0.18 | |
| Free cash flow per share | -0.75 | -0.73 | -0.69 | -0.5 | -0.25 | |
| Cash per share | 1.32 | 0.91 | 0.46 | 0.3 | 0.17 | |
| Book value per share | 1.54 | 1.09 | 0.62 | 0.48 | 0.37 | |
| Tangible book value per share | 1.28 | 0.85 | 0.4 | 0.27 | 0.37 | |
| Share holders equity per share | 1.54 | 1.09 | 0.62 | 0.48 | 0.37 | |
| Interest debt per share | 0 | 0 | 0 | 0.01 | 0.01 | |
| Market cap | 195.8M | 262.01M | 111.94M | 50.31M | 10.66M | |
| Enterprise value | 134.05M | 205.66M | 82.59M | 22.43M | -6.01M | |
| P/E ratio | -5.57 | -5.35 | -2.49 | -1.18 | -0.46 | |
| Price to sales ratio | 7.37K | 0 | 0 | 7.86 | 0 | |
| POCF ratio | -5.56 | -5.84 | -2.59 | -1.22 | -0.55 | |
| PFCF ratio | -5.55 | -5.82 | -2.54 | -1.02 | -0.41 | |
| P/B Ratio | 2.73 | 3.9 | 2.85 | 1.07 | 0.27 | |
| PTB ratio | 2.73 | 3.9 | 2.85 | 1.07 | 0.27 | |
| EV to sales | 5.05K | 0 | 0 | 3.5 | 0 | |
| Enterprise value over EBITDA | -4.02 | -4.36 | -1.91 | -0.56 | 0.31 | |
| EV to operating cash flow | -3.81 | -4.58 | -1.91 | -0.54 | 0.31 | |
| EV to free cash flow | -3.8 | -4.57 | -1.87 | -0.45 | 0.23 | |
| Earnings yield | -0.18 | -0.19 | -0.4 | -0.84 | -2.16 | |
| Free cash flow yield | -0.18 | -0.17 | -0.39 | -0.98 | -2.46 | |
| Debt to equity | 0 | 0 | 0 | 0.03 | 0.02 | |
| Debt to assets | 0 | 0 | 0 | 0.03 | 0.02 | |
| Net debt to EBITDA | 1.85 | 1.19 | 0.68 | 0.69 | 0.87 | |
| Current ratio | 18.48 | 11.35 | 4.66 | 6.26 | 4.01 | |
| Interest coverage | -128.81K | 0 | 0 | -1.29K | -588.38 | |
| Income quality | 1 | 0.92 | 0.96 | 0.97 | 0.84 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 1.05K | 0 | 0 | 5.59 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.16 | 0.21 | 0.3 | 0.38 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0.02 | 0.2 | 0.35 | |
| Capex to revenue | -1.37 | 0 | 0 | -1.28 | 0 | |
| Capex to depreciation | -0.02 | -0.09 | -0.5 | -3.64 | -2.69 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 5.1 | 4.4 | 3.13 | 2.15 | 1.34 | |
| ROIC | -0.49 | -0.73 | -1.15 | -0.85 | -0.55 | |
| Return on tangible assets | -0.55 | -0.86 | -1.4 | -1.31 | -0.53 | |
| Graham Net | 1.26 | 0.84 | 0.38 | 0.25 | 0.12 | |
| Working capital | 59.04M | 52.23M | 25.26M | 25.55M | 13.9M | |
| Tangible asset value | 60M | 52.25M | 25.28M | 26.82M | 38.96M | |
| Net current asset value | 59.04M | 52.23M | 25.26M | 24.83M | 13.83M | |
| Invested capital | 0 | 0 | 0 | 0.03 | 0.02 | |
| Average receivables | 313.22K | 583.87K | 682.5K | 702K | 538K | |
| Average payables | 2.86M | 2.14M | 2.9M | 2.53M | 1.83M | |
| Average inventory | 275.41K | 0 | 988.5K | 1.28M | 290.5K | |
| Days sales outstanding | 8.58K | 0 | 0 | 33.2 | 0 | |
| Days payables outstanding | 17.64 | 523.72 | 654.11 | 300.01 | 262.85 | |
| Days of inventory on hand | 0 | 0 | 402.23 | 94.63 | 0 | |
| Receivables turnover | 0.04 | 0 | 0 | 10.99 | 0 | |
| Payables turnover | 20.69 | 0.7 | 0.56 | 1.22 | 1.39 | |
| Inventory turnover | 0 | 0 | 0.91 | 3.86 | 0 | |
| ROE | -0.49 | -0.73 | -1.15 | -0.9 | -0.59 | |
| Capex per share | 0 | 0 | -0.01 | -0.08 | -0.06 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.07 | 0.01 | -0.01 | 0 | 0 | |
| Net income per share | -0.02 | -0.06 | -0.06 | -0.05 | -0.05 | |
| Operating cash flow per share | -0.04 | -0.05 | -0.06 | -0.04 | -0.04 | |
| Free cash flow per share | -0.12 | -0.07 | -0.08 | -0.06 | -0.05 | |
| Cash per share | 0.3 | 0.23 | 0.15 | 0.09 | 0.14 | |
| Book value per share | 0.48 | 0.42 | 0.36 | 0.32 | 0.3 | |
| Tangible book value per share | 0.27 | 0.2 | 0.06 | 0.07 | 0.3 | |
| Share holders equity per share | 0.48 | 0.42 | 0.36 | 0.32 | 0.3 | |
| Interest debt per share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Market cap | 50.31M | 51.02M | 65.96M | 17.72M | 12.96M | |
| Enterprise value | 22.43M | 29.96M | 52.06M | 10.2M | -3.71M | |
| P/E ratio | -5.87 | -2.13 | -2.8 | -0.85 | -0.46 | |
| Price to sales ratio | 7.86 | 35.7 | -46.16 | 0 | 0 | |
| POCF ratio | -12.77 | -10.52 | -12.08 | -4.18 | -2.39 | |
| PFCF ratio | -4.3 | -7.66 | -8.45 | -2.81 | -2.21 | |
| P/B Ratio | 1.07 | 1.25 | 1.88 | 0.56 | 0.33 | |
| PTB ratio | 1.07 | 1.25 | 1.88 | 0.56 | 0.33 | |
| EV to sales | 3.5 | 20.97 | -36.43 | 0 | 0 | |
| Enterprise value over EBITDA | -16.29 | -5.62 | -9.89 | -2.24 | 0.7 | |
| EV to operating cash flow | -5.69 | -6.18 | -9.54 | -2.41 | 0.68 | |
| EV to free cash flow | -1.92 | -4.5 | -6.67 | -1.62 | 0.63 | |
| Earnings yield | -0.04 | -0.12 | -0.09 | -0.29 | -0.54 | |
| Free cash flow yield | -0.23 | -0.13 | -0.12 | -0.36 | -0.45 | |
| Debt to equity | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Debt to assets | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Net debt to EBITDA | 20.25 | 3.95 | 2.64 | 1.65 | 3.16 | |
| Current ratio | 6.26 | 4.27 | 2.78 | 2.22 | 4.01 | |
| Interest coverage | -99.95 | -542.27 | -655.22 | -576.33 | -843 | |
| Income quality | 1.86 | 0.81 | 0.92 | 0.82 | 0.78 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.75 | 3.16 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.38 | 0.46 | 0.67 | 0.69 | 0 | |
| Capex to operating cash flow | 1.97 | 0.37 | 0.43 | 0.48 | 0.08 | |
| Capex to revenue | -1.21 | -1.26 | 1.64 | 0 | 0 | |
| Capex to depreciation | -10.76 | -2.85 | -3.7 | -3.24 | -0.7 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.48 | 0.77 | 0.69 | 0.62 | 0.61 | |
| ROIC | -0.04 | -0.14 | 0 | -0.16 | -0.15 | |
| Return on tangible assets | -0.07 | -0.23 | -0.5 | -0.47 | -0.16 | |
| Graham Net | 0.25 | 0.17 | 0.09 | 0.05 | 0.1 | |
| Working capital | 25.55M | 18.13M | 10.4M | 5.22M | 13.9M | |
| Tangible asset value | 26.82M | 19.49M | 5.48M | 6.57M | 38.96M | |
| Net current asset value | 24.83M | 17.52M | 9.96M | 4.98M | 13.83M | |
| Invested capital | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Average receivables | 577.5K | 601.5K | 584.5K | 555K | 528K | |
| Average payables | 3.13M | 2.06M | 2.1M | 2.03M | 1.98M | |
| Average inventory | 4K | 290.5K | 0 | 221K | 221K | |
| Days sales outstanding | 8.19 | 39.11 | -34.51 | 0 | 0 | |
| Days payables outstanding | 268.69 | 323.94 | -102.5 | 303.79 | 259.35 | |
| Days of inventory on hand | 84.75 | 0 | 0 | 62.74 | 0 | |
| Receivables turnover | 10.99 | 2.3 | -2.61 | 0 | 0 | |
| Payables turnover | 0.33 | 0.28 | -0.88 | 0.3 | 0.35 | |
| Inventory turnover | 1.06 | 0 | 0 | 1.43 | 0 | |
| ROE | -0.05 | -0.15 | -0.17 | -0.16 | -0.18 | |
| Capex per share | -0.08 | -0.02 | -0.02 | -0.02 | 0 |
CYXO.ST Frequently Asked Questions
What is Cyxone AB (publ) stock symbol ?
Cyxone AB (publ) is a SE stock and trading under the symbol CYXO.ST
What is Cyxone AB (publ) stock quote today ?
Cyxone AB (publ) stock price is $0.0868 today.
Is Cyxone AB (publ) stock public?
Yes, Cyxone AB (publ) is a publicly traded company.
Company Profile
- Volume Average 1.43M
- Market Capitalization 9.35M
- Employee 7
- CEO Mr. Carl-Magnus Hogerkorp
- Headquarters Malmö,SE
- IPO Date 2016-06-07
-
Website
https://www.cyxone.com 
Cyxone AB (publ), a clinical biotech company, develops disease modifying therapies for rheumatoid arthritis, multiple sclerosis, and treatments for virally induced acute respiratory disorders. Its development portfolio comprises Rabeximod in a clinical Phase II program for rheumatoid arthritis and Covid-19 infections; and T20K, a Phase 1 candidate drug for the treatment of multiple sclerosis. The company was incorporated in 2015 and is based in Malmö, Sweden.
